ACE2 – protein of the moment

May 20, 2020 New information on the cellular receptor for SARS-CoV-2 Two recent publications have reported important new data on ACE2, the cellular receptor protein for the SARS-CoV-2 virus. Although these studies were not carried out on COVID-19 patients, their findings may be high...

COVID-19 Technology Access Framework

The Broad Institute of MIT and Harvard has joined the “COVID-19 Technology Access Framework” organized by Harvard University, Massachusetts Institute of Technology, and Stanford University. Olink has been acknowledged as a critically important technology within this project and we are proud that ou...

ACE inhibition and COVID-19 – a Mendelian Randomization study

Preprint from new study now available on-line A study from Gill et al has found no evidence to support the hypothesis that the commonly used hypertension drugs known as ACE inhibitors may be of special relevance for COVID-19 patients, potentially increasing severity of the disease via regul...

View from the inside – SCALLOP pQTL CVD I study

An author’s perspective SCALLOP founder, Anders Mälarstig, talks about the consortium’s first major combined study, which was recently made available on bioRxiv The SCALLOP consortium is a collaborative framework for discovery and follow-up of genetic associations with p...

Large-scale pQTL study from SCALLOP

New major study now available on-line The SCALLOP consortium have recently completed a combined study that looks at protein quantitative trait loci (pQTL) for 90 cardiovascular proteins in over 30,000 individuals, identifying 467 pQTLs for 85 proteins: Folkerson et al, “Genom...

Beyond Mass Spec: Genomeweb article March 2020

An article in Genomeweb by Adam Bonislawski looks at an important shift in the technologies being used in proteomics research, which was until recently dominated heavily by mass spectrometry. With contributions from several leading lights in the scientific community, he describes ho...

Olink and the COVID-19 pandemic

Open for business while taking all necessary precautions! As a provider of protein biomarker solutions for scientists seeking to re-shape future healthcare, Olink is taking the COVID-19 pandemic situation extremely seriously, while maintaining its commitment to support crucial studies that will hel...

Heart to heart – Faiez Zannad in his own words

A story from the Olink user community. Professor Faiez Zannad, one of the world’s foremost researchers in the area of heart failure, talks about his work, the importance of protein biomarkers in his field, and about his experiences of working with Olink over a number of years....

The COLLIBRI consortium

February 4, 2020 COLLIBRI is a consortium that looks to accelerate progress in the field of inflammatory bowel disease through the use of protein biomarkers, engaging academic and industrial partners to share both clinical samples and the data obtained from relevant studies. The aim...

Landmark publication on the human sectretome

In a landmark  study from Matthias Uhlén’s group at KTH in Stockholm, a novel map of all proteins secreted to human blood was described. This provides a first comprehensive listing of all proteins secreted by the human cells. This map provides a unique resource to study human biology and disea...